OurGLP1 News
Original summaries of important research, regulation, availability, and safety updates. Every published story links to primary sources and shows its review status clearly.
10 September 2026
Novo Nordisk has reported the first topline results from its phase 3 STEP Young trial of semaglutide in children aged 6–11. We examine the 40.4% headline, the trial design and the important evidence still missing.
Read the sourced summary2 September 2026
A new Annals of Internal Medicine review brings together 38 randomized GLP-1 and co-agonist trials in adults without diabetes. We examine the weight-loss figures, safety findings and limits of cross-trial rankings.
Read the sourced summary30 August 2026
The FDA has expanded Mounjaro’s US label to include major cardiovascular risk reduction in high-risk adults with type 2 diabetes. We explain the SURPASS-CVOT evidence and its limits.
Read the sourced summary30 August 2026
Roche’s Genentech has licensed HM17321 in a deal potentially worth $2.3 billion. We examine the conditional economics, UCN2 mechanism and early evidence behind its muscle-preservation aim.
Read the sourced summary27 August 2026
A matched US claims study linked sustained tirzepatide use after age 55 with lower hospital and emergency-care spending. We examine the estimates, methods and important cost caveat.
Read the sourced summary21 August 2026
A randomized Phase II trial reported up to 9.7% average weight reduction with oral VCT220 at 16 weeks. We examine the dose response, titration, gastrointestinal effects and limitations.
Read the sourced summary20 August 2026
A 725-person Phase 3 trial reported greater average weight loss with survodutide than placebo at 76 weeks. We examine both analysis methods, tolerability and what remains unknown.
Read the sourced summary19 August 2026
A randomized trial and newer analyses raise an important question: are semaglutide's cardiovascular effects fully explained by weight loss? Here is what is established and what remains uncertain.
Read the sourced summary17 August 2026
Two systematic reviews found substantial average weight regain after GLP-1 treatment stopped. We examine the 60% estimate, longer-term projections and what remains unknown.
Read the sourced summary16 August 2026
In REIMAGINE 1, CagriSema reduced average HbA1c by up to 1.8 percentage points and body weight by 13.8% at 40 weeks. We examine the results, gastrointestinal effects and limitations.
Read the sourced summary14 August 2026
A peer-reviewed Phase 2b trial reported up to 12.1% average weight loss with daily aleniglipron at 36 weeks. We examine the design, tolerability and why Phase 3 evidence is still needed.
Read the sourced summary13 August 2026
Blood samples from 2,970 older SELECT participants produced a more favourable proteomic dementia-risk score with semaglutide. We explain why that is intriguing but not evidence of prevention.
Read the sourced summaryEvery published evidence summary remains available in the archive.
We report attributed findings, include study or regulatory context, explain uncertainty, distinguish research from approved clinical use, and avoid treatment recommendations.
Read our editorial policy